Stock comparison
Genmab A/S
Novartis AG
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.47B
Sector
Healthcare
NVS
Novartis AG
Market cap
$290.64B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | NVS | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 62C | GMAB |
| Benjamin Graham | 64C | 69B | NVS |
| Philip Fisher | 48D | 53C | NVS |
| Peter Lynch | 25F | 35D | NVS |
| Joel Greenblatt | 76B | 46D | GMAB |
| Charlie Munger | 68C | 69C | NVS |
| Terry Smith | 71C | 66B | GMAB |
Side-by-side metrics
| Metric | GMAB | NVS |
|---|---|---|
| Market cap | $16.47B | $290.64B |
| P/E (TTM) | 6.2x | 21.3x |
| EV/EBIT | 12.0x | 19.2x |
| ROIC (TTM) | 43.78% | 14.89% |
| Gross margin | 93.88% | 75.13% |
| Net margin | 18.23% | 24.31% |
| Revenue CAGR 5y | -18.45% | 5.66% |
| EPS CAGR 5y | -23.48% | -9.29% |
| Debt / Equity | 0.1x | 1.2x |
| Dividend yield | 0.0% | 3.12% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- Debt / Equity0.1xvs 1.2x+94%
- P/E (TTM)6.2xvs 21.3x+71%
- ROIC (TTM)43.78%vs 14.89%+66%
- EV/EBIT12.0xvs 19.2x+38%
NVS leads on
- Revenue CAGR 5y5.66%vs -18.45%+131%
- Dividend yield3.12%vs 0.0%+100%
- Market cap$290.64Bvs $16.47B+94%
- EPS CAGR 5y-9.29%vs -23.48%+60%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.